Oncology ImagingArchives
Integrated conventional ultrasound and radiomics model for predicting major pathological response to neoadjuvant therapy in triple-negative breast cancer
Oncology Imaging 4 min.
Triple-negative breast cancer (TNBC), a subtype with high malignancy and poor prognosis, accounts for approximately 15%-20% of all breast cancer subtypes [1]. Due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, TNBC is insensitive to endocrine therapy and HER2-targeted therapy....
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)
Oncology Imaging 1 min.
EAI141 was a prospective, multi-center trial designed to assess 3′-deoxy-3′-F-fluorothymidine (FLT) PET/CT as a treatment response biomarker. The primary was to evaluate the negative predictive value (NPV) of post-treatment ‘day 14' FLT-uptake (clinically non-responding patients with...
Multi-regional feature integration on enhanced CT for lymph node metastasis prediction in gastric cancer: a novel radiomics approach
Oncology Imaging 5 min.
Gastric cancer (GC) constitutes a major global health burden, ranking among the leading causes of cancer-related mortality. Recent epidemiological data reveal staggering annual estimates of 1.23 million new diagnoses and 954,000 deaths worldwide [1, 2], underscoring the urgent need for precision management...
AI-driven MRI biomarker for triple-class HER2 expression classification in breast cancer: a large-scale multicenter study
Oncology Imaging 5 min.
Breast cancer is the most prevalent malignancy and a leading cause of cancer-related mortality among women worldwide [1]. The human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in breast cancer, influencing both treatment response and disease progression [2,...
The feasibility of the radiomics models for tumor-infiltrating lymphocytes level prediction in breast cancer based on dynamic contrast-enhanced MRI
Oncology Imaging 5 min.
Breast cancer has emerged as the most prevalent malignant neoplasm globally and represents the second leading cause of cancer-related mortality among women worldwide [1]. Given the pronounced heterogeneity characteristic of breast cancer, the identification of optimal therapeutic strategies tailored...
